Benjamin Petro
Overview
Explore the profile of Benjamin Petro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petro B, Mahmud D, Taioli S, Ganapathy A, Senyuk V, Yoshinaga K, et al.
J Immunol
. 2019 Mar;
202(8):2493-2501.
PMID: 30842275
The limited number of hematopoietic stem cells (HSC) within a single unit of human cord blood currently limits its use as an alternate graft source. However, we have developed a...
2.
Mahmud N, Khanal A, Taioli S, Koca E, Gaitonde S, Petro B, et al.
PLoS One
. 2018 Nov;
13(11):e0206980.
PMID: 30496309
In this study we utilized a large animal model to identify a dose of intravenous busulfan that can cause reversible myelosuppression. Nine baboons (Papio anubis) were treated with IV busulfan...
3.
Saraf S, Araki H, Petro B, Park Y, Taioli S, Yoshinaga K, et al.
Transfusion
. 2014 Nov;
55(4):864-74.
PMID: 25363624
Background: Epigenetic modifications likely control the fate of hematopoietic stem cells (HSCs). The chromatin-modifying agents (CMAs), 5-aza-2'-deoxycytidine (5azaD) and trichostatin A (TSA), have previously been shown to expand HSCs from...
4.
Mahmud N, Petro B, Baluchamy S, Li X, Taioli S, Lavelle D, et al.
Biol Blood Marrow Transplant
. 2013 Dec;
20(4):480-9.
PMID: 24374212
Epigenetic therapies, including DNA methyltransferase and histone deacetylase (HDAC) inhibitors, are increasingly being considered to treat hematological malignancies, but their effects on normal hematopoietic stem cells (HSCs) remain largely unexplored....
5.
Araki H, Chute J, Petro B, Halliday L, Hoffman R, Mahmud N
Leuk Lymphoma
. 2010 May;
51(6):1121-7.
PMID: 20470216
Increased cell dose has a positive impact on the therapeutic outcome of bone marrow (BM) hematopoietic stem cell (HSC) transplant. However, methods to successfully expand BM HSCs have yet to...
6.
Araki H, Baluchamy S, Yoshinaga K, Petro B, Petiwala S, Parajuli R, et al.
Exp Hematol
. 2009 Jun;
37(9):1084-95.
PMID: 19501128
Objective: Augmentation of the number of cord blood (CB) hematopoietic stem cells (HSC) present in a unit is required before it can be considered as an alternative graft for hematopoietic...